Literature DB >> 26807968

Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing.

Maria Casadellà1, Marc Noguera-Julian, Henry Sunpath, Michelle Gordon, Cristina Rodriguez, Mariona Parera, Daniel R Kuritzkes, Vincent C Marconi, Roger Paredes.   

Abstract

In a South African cohort of participants living with HIV developing virological failure on first-line tenofovir disoproxyl fumarate (TDF)-based regimens, at least 70% of participants demonstrated TDF resistance according to combined Sanger and MiSeq genotyping. Sanger sequencing missed the K65R mutation in 30% of samples. Unless HIV genotyping is available to closely monitor epidemiological HIV resistance to TDF, its efficacy as second-line therapy will be greatly compromised.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26807968      PMCID： PMC5884087          DOI： 10.1097/QAD.0000000000001033

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  12 in total

1.  High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen.

Authors:  Henry Sunpath; Baohua Wu; Michelle Gordon; Jane Hampton; Brent Johnson; Mahomed-Yunus S Moosa; Claudia Ordonez; Daniel R Kuritzkes; Vincent C Marconi
Journal:  AIDS       Date:  2012-08-24       Impact factor: 4.177

2.  Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C.

Authors:  Cédric F Invernizzi; Dimitrios Coutsinos; Maureen Oliveira; Daniela Moisi; Bluma G Brenner; Mark A Wainberg
Journal:  J Infect Dis       Date:  2009-10-15       Impact factor: 5.226

3.  HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.

Authors:  Bluma G Brenner; Maureen Oliveira; Florence Doualla-Bell; Daniela D Moisi; Michel Ntemgwa; Fernando Frankel; Max Essex; Mark A Wainberg
Journal:  AIDS       Date:  2006-06-12       Impact factor: 4.177

4.  Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903.

Authors:  N A Margot; B Lu; A Cheng; M D Miller
Journal:  HIV Med       Date:  2006-10       Impact factor: 3.180

5.  Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.

Authors:  Nicolas A Margot; Erica Isaacson; Ian McGowan; Andrew K Cheng; Robert T Schooley; Michael D Miller
Journal:  AIDS       Date:  2002-06-14       Impact factor: 4.177

6.  Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate.

Authors:  Damian J McColl; Nicolas A Margot; Michael Wulfsohn; Dion F Coakley; Andrew K Cheng; Michael D Miller
Journal:  J Acquir Immune Defic Syndr       Date:  2004-11-01       Impact factor: 3.731

7.  High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa.

Authors:  Lindiwe Skhosana; Kim Steegen; Michelle Bronze; Azwidowi Lukhwareni; Esrom Letsoalo; Maria A Papathanasopoulos; Sergio C Carmona; Wendy S Stevens
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

8.  Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.

Authors:  Soo-Yon Rhee; Jose Luis Blanco; Michael R Jordan; Jonathan Taylor; Philippe Lemey; Vici Varghese; Raph L Hamers; Silvia Bertagnolio; Tobias F Rinke de Wit; Avelin F Aghokeng; Jan Albert; Radko Avi; Santiago Avila-Rios; Pascal O Bessong; James I Brooks; Charles A B Boucher; Zabrina L Brumme; Michael P Busch; Hermann Bussmann; Marie-Laure Chaix; Bum Sik Chin; Toni T D'Aquin; Cillian F De Gascun; Anne Derache; Diane Descamps; Alaka K Deshpande; Cyrille F Djoko; Susan H Eshleman; Herve Fleury; Pierre Frange; Seiichiro Fujisaki; P Richard Harrigan; Junko Hattori; Africa Holguin; Gillian M Hunt; Hiroshi Ichimura; Pontiano Kaleebu; David Katzenstein; Sasisopin Kiertiburanakul; Jerome H Kim; Sung Soon Kim; Yanpeng Li; Irja Lutsar; Lynn Morris; Nicaise Ndembi; Kee Peng Ng; Ramesh S Paranjape; Martine Peeters; Mario Poljak; Matt A Price; Manon L Ragonnet-Cronin; Gustavo Reyes-Terán; Morgane Rolland; Sunee Sirivichayakul; Davey M Smith; Marcelo A Soares; Vincent V Soriano; Deogratius Ssemwanga; Maja Stanojevic; Mariane A Stefani; Wataru Sugiura; Somnuek Sungkanuparph; Amilcar Tanuri; Kok Keng Tee; Hong-Ha M Truong; David A M C van de Vijver; Nicole Vidal; Chunfu Yang; Rongge Yang; Gonzalo Yebra; John P A Ioannidis; Anne-Mieke Vandamme; Robert W Shafer
Journal:  PLoS Med       Date:  2015-04-07       Impact factor: 11.069

9.  Assessment of second-line antiretroviral regimens for HIV therapy in Africa.

Authors:  Nicholas I Paton; Cissy Kityo; Anne Hoppe; Andrew Reid; Andrew Kambugu; Abbas Lugemwa; Joep J van Oosterhout; Mary Kiconco; Abraham Siika; Raymond Mwebaze; Mary Abwola; George Abongomera; Aggrey Mweemba; Hillary Alima; Dickens Atwongyeire; Rose Nyirenda; Justine Boles; Jennifer Thompson; Dinah Tumukunde; Ennie Chidziva; Ivan Mambule; Jose R Arribas; Philippa J Easterbrook; James Hakim; A Sarah Walker; Peter Mugyenyi
Journal:  N Engl J Med       Date:  2014-07-17       Impact factor: 91.245

10.  Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens.

Authors:  Gert U Van Zyl; Tommy F Liu; Mathilda Claassen; Susan Engelbrecht; Tulio de Oliveira; Wolfgang Preiser; Natasha T Wood; Simon Travers; Robert W Shafer
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240
View more
  9 in total

Review 1.  The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure.

Authors:  Natalia Stella-Ascariz; José Ramón Arribas; Roger Paredes; Jonathan Z Li
Journal:  J Infect Dis       Date:  2017-12-01       Impact factor: 5.226

2.  Next-Generation Human Immunodeficiency Virus Sequencing for Patient Management and Drug Resistance Surveillance.

Authors:  Marc Noguera-Julian; Dianna Edgil; P Richard Harrigan; Paul Sandstrom; Catherine Godfrey; Roger Paredes
Journal:  J Infect Dis       Date:  2017-12-01       Impact factor: 5.226

3.  No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom.

Authors:  Ellen White; Erasmus Smit; Duncan Churchill; Simon Collins; Clare Booth; Anna Tostevin; Caroline Sabin; Deenan Pillay; David T Dunn
Journal:  J Infect Dis       Date:  2016-05-24       Impact factor: 5.226

4.  HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.

Authors:  Cissy Kityo; Jennifer Thompson; Immaculate Nankya; Anne Hoppe; Emmanuel Ndashimye; Colin Warambwa; Ivan Mambule; Joep J van Oosterhout; Kara Wools-Kaloustian; Silvia Bertagnolio; Philippa J Easterbrook; Peter Mugyenyi; A Sarah Walker; Nicholas I Paton
Journal:  J Acquir Immune Defic Syndr       Date:  2017-06-01       Impact factor: 3.731

5.  Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.

Authors:  Dami Collier; Collins Iwuji; Anne Derache; Tulio de Oliveira; Nonhlanhla Okesola; Alexandra Calmy; Francois Dabis; Deenan Pillay; Ravindra K Gupta
Journal:  Clin Infect Dis       Date:  2017-04-15       Impact factor: 9.079

6.  CODEHOP-Mediated PCR Improves HIV-1 Genotyping and Detection of Variants by MinION Sequencing.

Authors:  Horeyah Sarkhouh; Wassim Chehadeh
Journal:  Microbiol Spectr       Date:  2021-10-20

7.  Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria.

Authors:  Kate El Bouzidi; Rawlings P Datir; Vivian Kwaghe; Sunando Roy; Dan Frampton; Judith Breuer; Obinna Ogbanufe; Fati Murtala-Ibrahim; Man Charurat; Patrick Dakum; Caroline A Sabin; Nicaise Ndembi; Ravindra K Gupta
Journal:  J Antimicrob Chemother       Date:  2022-02-02       Impact factor: 5.790

8.  Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.

Authors:  John Gregson; Pontiano Kaleebu; Vincent C Marconi; Cloete van Vuuren; Nicaise Ndembi; Raph L Hamers; Phyllis Kanki; Christopher J Hoffmann; Shahin Lockman; Deenan Pillay; Tulio de Oliveira; Nathan Clumeck; Gillian Hunt; Bernhard Kerschberger; Robert W Shafer; Chunfu Yang; Elliot Raizes; Rami Kantor; Ravindra K Gupta
Journal:  Lancet Infect Dis       Date:  2016-12-01       Impact factor: 25.071

9.  HIV drug resistance patterns in pregnant women using next generation sequence in Mozambique.

Authors:  María Rupérez; Marc Noguera-Julian; Raquel González; Sonia Maculuve; Rocío Bellido; Anifa Vala; Cristina Rodríguez; Esperança Sevene; Roger Paredes; Clara Menéndez
Journal:  PLoS One       Date:  2018-05-09       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.